ENTITY

Sichuan Biokin Pharmaceutical Co Ltd (SBP12 HK)

2
Analysis
Health CareHong Kong
more
27 Feb 2024 11:51Syndicated

CX Daily: Chinese Pharma Turns to Global Deals to Cure Capital Crunch

Biotech / Cover story: Chinese pharma turns to global deals to cure capital crunch After enduring the chill of a prolonged capital winter, China’s...

Logo
236 Views
Share
25 Feb 2024 10:00

STAR50 Index Rebalance: Three Changes a Side; One Surprise Change

There are 3 changes for the STAR50 in March. Estimated one-way turnover is 2.9% resulting in a 1-way trade of CNY 4.08bn with over 2.5x ADV to...

Logo
608 Views
Share
13 Feb 2024 08:46

China Healthcare Weekly (Feb.12) - New Pricing Mechanism for Drugs, China Biotech M&A, Medicilon

NHSA released regulations to establish new mechanism for pricing newly listed chemical drugs. It would be difficult for Chinese biotech to be...

Logo
412 Views
Share
01 Feb 2024 07:18

STAR50 Index Rebalance Preview: Sustaining Outperformance on Expected Impact

There could be 3 changes for the STAR50 Index in March. One-way turnover is estimated at 2.4% leading to a one-way trade of CNY 2.9bn. The...

Logo
618 Views
Share
bearishRemegen
23 Jan 2024 08:55

Remegen (9995.HK/688331.CH) - The Real Reasons for the Stock Price Collapse and the Future Prospects

RemeGen's 23Q4 results will miss expectation, leading to poor performance for 2023.The pain point isn't cashflow shortage but weak...

Logo
356 Views
Share
x